DEKA BioSciences is developing personalized therapeutics for cancer and inflammatory diseases. The body’s natural defense system has the potential to treat various diseases if the right components can be activated. DEKA has created their DiakineTM platform to identify naturally occurring proteins that help regulate the immune system. DiakinesTM comprise a human single-chain variable antibody fragment that links to a combination of cytokines that stimulate the immune system. This modular approach enables DEKA to account for patient differences in cytokine responses. From a single genetic test, DEKA hopes physicians will be able to know what DiakineTM will be the most effective for each patient.

Deka Biosciences

 Germantown’s Deka Biosciences closes $20M financing round 


				Deka Biosciences Breaks Ground on New Facility			

We are thrilled to share that Deka will be presenting at this week’s Immuno-Oncology Summit in Philadelphia! If you’re attending, we invite you to join us for the following sessions:
 
Tumor Microenvironment Track: “Detoxifying and Improving IL-2 Potency through Combination with IL-10 and Targeting to the TME,” presented by John Mumm, PhD.
 
Emerging Tech for IO Targeting and Discovery Track: “Ramifications of Tethering T Cell-Activating Cytokines to the Surface of Tumor Cells,” presented by Jacob McCright, PhD.
 
We look forward to connecting with you and sharing our latest research advancements.

#IOSummit #immunooncology #cancerresearch #drugdevelopment

 /C O R R E C T I O N — Deka Biosciences/ 

 FDA awards nearly $7.5 million to pediatric device consortium ... 

Deka Biosciences Raises USD 20 Million in Series A Financing - PR Newswire

Deka Biosciences secures $20m to advance product pipeline - Pharmaceutical Technology

Deka Biosciences Announces First-in-Human Dose in Phase 1 Clinical Trial of DK210 (EGFR) - PR Newswire

Deka's IND for DK-210 (EGFR) in advanced solid cancer receives FDA clearance - BioWorld Online

We are excited to share that Deka, along with our partners, will be presenting two posters at SITC 2024! Will we see you there? #SITC24

The Deka team had a fantastic time at SITC last week, sharing our latest research with two poster presentations. Thank you to everyone who stopped by to connect with us. To view the posters, visit our website: https://lnkd.in/dKxdkb5y

#SITC24

 Dual cytokine fusion proteins comprising multi-subunit cytokines 

 Deka Biosciences Raises USD 20 Million in Series A Financing 

Our Scientist, Jacob McCright, presenting on day 2 of Cytokine-Based Drug Development Summit. What a wonderful way to end this insightful summit! 

#cytokinedrugdevelopment

 Deka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of Directors 

 Deka Biosciences Appoints Chief Medical Officer and Vice President of Clinical Operations 

Our CEO, Dr. John Mumm, presented at the SAPA-DC 2024 Annual Conference this past weekend, delivering an insightful presentation titled "Paradigm Shift for Therapeutic Use of Cytokines."

Grateful to have been a part of such an inspiring event, where thought leaders are driving meaningful change in biotech. Thank you, SAPA-DC, for having us!

#Biotech #Cytokines #Innovation #Leadership #SAPA_DC #DekaBiosciences

It was an honor to present our poster at ASCO this weekend, sharing the initial results from our Phase 1 clinical trial of DK2¹⁰ (EGFR). A heartfelt thank you to our many partners and collaborators who have made this possible, including: Dr. Alexander I. Spira, Dr. Siqing Fu, Dr. Abdul Rafeh Naqash, Dr. Adanma Ayanambakkam, Dr. Syed Mohammad Ali Kazmi, Dr. Abhishek Tripathi, Dr. Aurelien Marabelle, Dr. Xinhua Zhu, and Dr. Douglas W. Orr. Your support and dedication have been instrumental in our progress.

#ASCO2024 #ClinicalResearch #ClinicalTrial #Oncology


				Deka Biosciences Closes USD $20 Million Series B2 Financing Led by MPM BioImpact			

We are thrilled to be in Houston this week for #SITC24! A reminder that we will be presenting two posters on Friday, showcasing our latest research.

If you're attending the conference, please stop by to learn more about our advancements and connect with our team. 

We are thrilled to welcome Dr. Jacques Banchereau to Deka’s Scientific Advisory Board!

Dr. Banchereau, a globally recognized leader in immunology, brings over four decades of experience in both academic and industry settings. His groundbreaking contributions to our understanding of cytokines, inflammation, and systems immunology have significantly advanced the field.

With a focus on the discovery and characterization of human cytokines and the biology of B-cells and dendritic cells, Dr. Banchereau has made significant strides in vaccine development and immune therapies. His expertise in areas such as cancer and autoimmune diseases will be a tremendous asset to Deka as we continue to innovate and drive forward cutting-edge solutions in healthcare and science.

We're excited to have Dr. Banchereau on board and look forward to his valuable contributions. Join us in welcoming Dr. Banchereau to the team!

 Deka Biosciences Closes USD $20 Million Series B2 Financing Led by MPM BioImpact 


				Deka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of Directors			

 Deka Biosciences, Inc on LinkedIn: Our CBO, Pavel Khrimian is currently attending the US Pharma and Biotech… 

 Meet Bethesda Magazine's 2023 Women Who Inspire 

 Use of dual cytokine fusion proteins comprising il-10 and adoptive cell … 


				Deka Biosciences Announces First-in-Human Dose in Phase 1 Clinical Trial of DK210 (EGFR)			

 Deka Biosciences advances its lead dual cytokine therapy candidate 

Deka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of Directors - PR Newswire

We're proud to share our latest research at #SITC2024 with two different posters. One of them, titled "Balanced Diakine™ targeted cytokines localize within the immunological synapse and augment immune response in combination with T cell engagers," will be presented by Dr. Jacob McCright from Deka.

A huge thank you to Jacob and the incredible team behind this work: Steven Dudics, Alice Hsu, David Langan, Benjamin George, Phillip Kuri, Antony Haider, Karen Huang, Fatima Hamdan, Javier Goitia, Julie Ahn, Christopher Yaen, Stanley Frankel, and John Mumm. Together, we’re advancing the field of immunotherapy by exploring new ways to strengthen immune responses and develop more effective treatments for patients.

#Biotech #Cytokines #CancerResearch #DekaBiosciences

Dr. Abdul Rafeh Naqash from Stephenson Cancer Center at Oklahoma University will be presenting one of our #SITC2024 posters, titled “Immune Biomarkers from Phase 1 First-in-Human Trial Treating Advanced Cancer Patients with DK2¹⁰(EGFR) compared to ex vivo Diakine™ Response Assay,” sharing key insights from our Phase 1 clinical trial.

Thank you, Dr. Naqash, and the brilliant team behind this research: Adanma Ayanambakkam, Alexander Spira, Syed Kazmi, Douglas Orr, Xinhua Zhu, Siqing Fu, Abhishek Tripathi, Aurelien Marabelle, David Langan, Alice Hsu, Jacob McCright, Steven Dudics, Fatima Hamdan, Benjamin George, Phillip Kuri, Allison Long, Deb Kientop, Stanley Frankel, and John Mumm. 

#CancerResearch #Biotech #Immunotherapy #DekaBiosciences

 Endpoints News — #1809- Sernova, CellTrans bet big on type ... 

 Deka Biosciences Breaks Ground on New Facility 

Deka Biosciences Appoints Chief Medical Officer and Vice President of Clinical Operations - PR Newswire

 Big biotech and a mapping megaround: Here are DC’s top ... 

Deka Biosciences Closes USD $20 Million Series B2 Financing Led by MPM BioImpact - PR Newswire

 Deka Biosciences: $20 Million Secured To Maximize Patient Benefits Through Improved Pharmacokinetics 

 Deka Biosciences, Inc on LinkedIn: Deka Employee Spotlight: Javier Goitia Javier is a Research Associate at… 

 Deka Biosciences, Inc on LinkedIn: We are pleased to welcome Dr. Abhishek Tripathi to our Scientific Advisory… 

 Dual cytokine fusion proteins comprising il-10 

 Method of reducing bispecific t cell engager or chimeric antigen receptor t … 

 Il-10 variant molecules and methods for treating inflammatory disease and … 

Deka Biosciences Receives FDA Clearance of DK210 (EGFR) Investigational New Drug Application - PR Newswire

Deka Biosciences

Business:

Drug notes:

About: